Independent Real-World Experience from Nigeria Supports Continued Scientific Evaluation of ErpeCream®
Observational clinical experience collected by an independent physician contributes additional real-world insights into the use of ErpeCream® in patients with recurrent HSV infections.
ACS Produzioni Biomed S.r.l. (“ACS Biomed”), an Italian biotechnology company focused on innovative topical solutions for Herpes Simplex Virus (HSV) infections, has received the findings of an independent observational experience conducted by a microbiology physician in Nigeria involving patients affected by recurrent HSV infections.
The observational programme was designed to document routine clinical use of ErpeCream® under real-world conditions. While not intended as a registrational clinical trial, the experience provides additional practical information that complements the company's ongoing scientific and clinical development activities.
Real-world evidence plays an increasingly important role in understanding how healthcare products perform outside controlled clinical environments. When interpreted alongside laboratory research and formal clinical studies, observational experience can provide valuable insights into product use in everyday clinical practice.
Observational Experience in Clinical Practice
The Nigerian observational programme involved patients treated within routine medical practice under the supervision of an independent physician with expertise in microbiology.
The experience focused on documenting product use and clinical observations rather than testing predefined regulatory endpoints.
As an observational initiative, the programme was not designed to establish efficacy for regulatory purposes. Instead, it provides complementary information that may help guide future scientific investigation and product development.
Complementing Ongoing Research
ACS Biomed continues to build its scientific evidence through multiple complementary sources, including independent laboratory studies, clinical development programmes and real-world medical observations.
Each source of information contributes differently to the understanding of the company's proprietary technology platform.
The observational experience from Nigeria therefore represents an additional element within a broader research strategy aimed at strengthening the scientific knowledge surrounding ErpeCream® while supporting future development activities.
Continuing International Scientific Development
The company remains committed to advancing ErpeCream® through a structured programme of scientific research, clinical development and international collaboration.
Together with ongoing regulatory initiatives and the Phase IIb clinical programme, independent observational experience contributes to ACS Biomed's objective of continuously expanding the evidence supporting its proprietary HSV technology.
By combining laboratory research, clinical investigation and real-world medical experience, ACS Biomed continues to pursue a comprehensive development strategy focused on delivering innovative solutions for the management of recurrent Herpes Simplex Virus infections.